TEVA Company Profile

What is the competitive landscape for TEVA, and when can generic versions of TEVA drugs launch?

TEVA has seven hundred and forty approved drugs.

There are one hundred and three US patents protecting TEVA drugs. There are fifty-three tentative approvals on TEVA drugs.

There are nine hundred and forty-four patent family members on TEVA drugs in forty-nine countries and one thousand and eighty-five supplementary protection certificates in eighteen countries.

Summary for TEVA

International Patents:	944
US Patents:	103
Tradenames:	510
Ingredients:	445
NDAs:	740
Patent Litigation for TEVA:	See patent lawsuits for TEVA
PTAB Cases with TEVA as petitioner:	See PTAB cases with TEVA as petitioner

Drugs and US Patents for TEVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	FLUCONAZOLE	fluconazole	TABLET;ORAL	074681-001	Jul 29, 2004		DISCN	No	No
Teva	BETAMETHASONE DIPROPIONATE	betamethasone dipropionate	OINTMENT;TOPICAL	071477-001	Aug 10, 1987		DISCN	No	No
Teva Branded Pharm	ZECUITY	sumatriptan succinate	SYSTEM;IONTOPHORESIS	202278-001	Jan 17, 2013		DISCN	Yes	No	7,973,058
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-003	Jan 27, 2017		RX	Yes	Yes	10,765,820*PED				Y
Teva	PHENTERMINE HYDROCHLORIDE	phentermine hydrochloride	CAPSULE;ORAL	088614-001	Apr 9, 1984		DISCN	No	No
Teva Pharm	AIRDUO DIGIHALER	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-006	Jul 12, 2019		DISCN	Yes	No	8,978,966*PED				Y
Teva	UZEDY	risperidone	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	213586-003	Apr 28, 2023		RX	Yes	No	9,925,268		Y

Expired US Patents for TEVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Pharms Usa	COPAXONE	glatiramer acetate	FOR SOLUTION;SUBCUTANEOUS	020622-001	Dec 20, 1996	6,054,430
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-002	Dec 17, 2014	5,776,432
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-003	Jan 28, 2014	6,054,430
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-003	Jan 27, 2017	6,718,972
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-003	Jan 27, 2017	6,871,646
Teva Branded Pharm	PROAIR RESPICLICK	albuterol sulfate	POWDER, METERED;INHALATION	205636-001	Mar 31, 2015	8,006,690
Teva Pharms Usa	COPAXONE	glatiramer acetate	FOR SOLUTION;SUBCUTANEOUS	020622-001	Dec 20, 1996	7,199,098

Paragraph IV (Patent) Challenges for TEVA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	for Injection	100 mcg/vial and 500 mcg/vial		2015-04-14
	Tablets	1 mg/0.02 mg and 75 mg		2006-04-17
	Delayed-release Tablets	20 mg		2015-06-03
	Tablets	5 mg, 10 mg, 20 mg, 30 mg		2009-11-18
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-02-26
	Tablets	0.15 mg/0.03 mg/0.01 mg		2008-01-22
	Tablets	0.1 mg/0.02 mg and 0.01 mg		2009-11-16
	for Injection	200 mcg/vial		2015-05-01
	for Injection	3.5 mg/vial		2016-10-26
	Tablets	0.5 mg and 1 mg		2010-05-17
	Extended-release Capsule	15 mg and 30 mg		2008-08-11
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-01-29
	Tablets	0.15 mg/0.03 mg		2004-03-29
	Tablets	0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg		2013-07-10

Premature patent expirations for TEVA

Expiration due to failure to pay maintenance fee

Patent Number	Expiration Date

International Patents for TEVA Drugs

Country	Patent Number	Estimated Expiration
South Korea	101618931
European Patent Office	2073795
Hong Kong	1219067
San Marino	T201500026
Peru	20230852
Hungary	E042305
Portugal	3265085

Supplementary Protection Certificates for TEVA Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1453521	CA 2016 00016	Denmark		PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
1255752	91407	Luxembourg		PRODUCT NAME: SUNITINIB, OPTIONNELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, Y COMPRIS LE SEL L-MALATE (SUTENT ); AUTHORISATION NUMBER AND DATE: EU/1/06/347/001-003 - SUTENT-SUNITINIB 20060724
2435025	LUC00124	Luxembourg		PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220
0206283	C980016	Netherlands		PRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606
3300601	2022C/528	Belgium		PRODUCT NAME: COMBINATIE VAN DAUNORUBICINE EN CYTARABINE; AUTHORISATION NUMBER AND DATE: EU/1/18/1308 20180827
1532149	C300569	Netherlands		PRODUCT NAME: LINAGLIPTINE, DESGEWENST IN DE VORM VAN EEN ZOUT, IN COMBINATIE MET METFORMINEHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/12/780/001-028 20120720
0566709	SPC/GB04/012	United Kingdom		PRODUCT NAME: TRAMADOL HYDROCHLORIDE, PARACETAMOL; REGISTERED: FR NL 25970 20020405; UK PL 00242/0384 20030925

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Teva
• Teva Branded Pharm
• Teva Parenteral
• Teva Pharm
• Teva Pharms
• Teva Pharms Inc
• Teva Pharms Intl